Arsenic trioxide
-
Subject Areas on Research
- A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
- A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
- Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.
- Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
- Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
- Arsenic trioxide uptake by human and rat aquaglyceroporins.
- Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
- Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
- Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9.
- Interlaboratory validation of a new assay for DNA-protein crosslinks.
- Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
- Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
- Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.